Gain Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Bethesda, MD
GANX chart
What traders are saying about $GANX
Latest postsGain Therapeutics, Inc. news
- Gain Therapeutics Stock Price Forecast. Should You Buy GANX?
StockInvest.us ·
- Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates
kalkine.ca ·
- Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Yahoo Finance ·
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Yahoo Finance ·
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Yahoo Finance ·
- Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Yahoo Finance ·
- Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Yahoo Finance ·
- Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Yahoo Finance ·
- Why Is GANX Stock Rallying 22% After Hours?
stocktwits.com ·
- Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Yahoo Finance ·
- Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Yahoo Finance ·
Gain Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $55,180 | $132,640 |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M |
| Diluted EPS | $-0.61 | $-0.89 | $-1.71 | $-1.48 |
| Total assets (year end) | $22.8M | $12.1M | $18.6M | $24.1M |
| Cash and equivalents (year end) | $20.8M | $10.4M | $11.8M | $7.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Gain Therapeutics, Inc.
- Ticker
- GANX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Bethesda, MD
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1819411
Frequently asked questions
What exchange is Gain Therapeutics, Inc. listed on?
Gain Therapeutics, Inc. trades on the Nasdaq under the ticker symbol GANX.
What industry is Gain Therapeutics, Inc. in?
Gain Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc.'s business address on file with the SEC is in Bethesda, MD.
When does Gain Therapeutics, Inc.'s fiscal year end?
Gain Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Gain Therapeutics, Inc. report?
Gain Therapeutics, Inc. reported $55,180 in revenue for calendar year 2023, according to its SEC filings.